Replimune to Present at Two Upcoming Investor Conferences
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies, has announced its participation in two upcoming investor conferences. The company's management team will be presenting and hosting investor meetings at these events:
1. BMO 2024 Oncology Summit on Tuesday, October 8, 2024
2. 3rd Annual Roth Healthcare Opportunities Conference on Wednesday, October 9, 2024
These conferences provide Replimune with an opportunity to showcase its progress in the field of oncolytic immunotherapies and engage with investors. The company's presence at these events underscores its commitment to advancing its clinical-stage pipeline and maintaining open communication with the investment community.
Replimune Group, Inc. (Nasdaq: REPL), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di innovative immunoterapie oncolitiche, ha annunciato la sua partecipazione a due prossime conferenze per investitori. Il team di gestione dell'azienda presenterà e ospiterà incontri con gli investitori durante questi eventi:
1. BMO 2024 Oncology Summit martedì 8 ottobre 2024
2. 3ª Annual Roth Healthcare Opportunities Conference mercoledì 9 ottobre 2024
Queste conferenze offrono a Replimune l'opportunità di mostrare i suoi progressi nel campo delle immunoterapie oncolitiche e di coinvolgere gli investitori. La presenza dell'azienda a questi eventi sottolinea il suo impegno nell'avanzare il proprio pipeline in fase clinica e nel mantenere una comunicazione aperta con la comunità degli investitori.
Replimune Group, Inc. (Nasdaq: REPL), una empresa biotecnológica en fase clínica centrada en el desarrollo de novedosas inmunoterapias oncolíticas, ha anunciado su participación en dos próximas conferencias para inversores. El equipo de gestión de la empresa presentará y llevará a cabo reuniones con inversores en estos eventos:
1. BMO 2024 Oncology Summit el martes 8 de octubre de 2024
2. 3ª Conferencia Anual Roth de Oportunidades en el Cuidado de la Salud el miércoles 9 de octubre de 2024
Estas conferencias ofrecen a Replimune la oportunidad de mostrar sus avances en el campo de las inmunoterapias oncolíticas y de interactuar con los inversores. La presencia de la empresa en estos eventos subraya su compromiso de avanzar en su pipeline en fase clínica y de mantener una comunicación abierta con la comunidad inversora.
Replimune Group, Inc. (Nasdaq: REPL)은 혁신적인 온콜리틱 면역 요법 개발에 중점을 둔 임상 단계 생명공학 회사로, 다가오는 두 개의 투자자 회의에 참여한다고 발표했습니다. 회사의 관리 팀은 이 행사에서 발표하고 투자자 회의를 주최할 예정입니다:
1. BMO 2024 Oncology Summit 2024년 10월 8일 화요일
2. 제3회 Annual Roth Healthcare Opportunities Conference 2024년 10월 9일 수요일
이 회의는 Replimune가 온콜리틱 면역 요법 분야의 발전을 알리고 투자자와 교류할 수 있는 기회를 제공합니다. 이러한 행사에 대한 회사의 참석은 임상 단계 파이프라인을 발전시키고 투자자 커뮤니티와의 열린 소통을 유지하려는 의지를 강조합니다.
Replimune Group, Inc. (Nasdaq: REPL), une entreprise de biotechnologie en phase clinique axée sur le développement de nouvelles immunothérapies oncolytiques, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'équipe de direction de l'entreprise présentera et accueillera des réunions avec les investisseurs lors de ces événements :
1. BMO 2024 Oncology Summit le mardi 8 octobre 2024
2. 3ème Conférence Annuelle Roth sur les Opportunités en Santé le mercredi 9 octobre 2024
Ces conférences offrent à Replimune l'opportunité de mettre en avant ses progrès dans le domaine des immunothérapies oncolytiques et d'interagir avec les investisseurs. La présence de l'entreprise à ces événements souligne son engagement à faire avancer son pipeline en phase clinique et à maintenir une communication ouverte avec la communauté des investisseurs.
Replimune Group, Inc. (Nasdaq: REPL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger onkolytischer Immuntherapien konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Managementteam des Unternehmens wird auf diesen Veranstaltungen präsentieren und Investorenmeetings veranstalten:
1. BMO 2024 Oncology Summit am Dienstag, den 8. Oktober 2024
2. 3. Annual Roth Healthcare Opportunities Conference am Mittwoch, den 9. Oktober 2024
Diese Konferenzen bieten Replimune die Möglichkeit, seine Fortschritte im Bereich der onkolytischen Immuntherapien zu präsentieren und mit Investoren in Kontakt zu treten. Die Präsenz des Unternehmens bei diesen Veranstaltungen unterstreicht sein Engagement für die Weiterentwicklung seiner klinischen Pipeline und den offenen Austausch mit der Investmentgemeinschaft.
- None.
- None.
WOBURN, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
BMO 2024 Oncology Summit
Date: Tuesday, October 8, 2024
3rd Annual Roth Healthcare Opportunities Conference
Date: Wednesday, October 9, 2024
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
Which investor conferences will Replimune (REPL) attend in October 2024?
What is Replimune's (REPL) focus as a biotechnology company?
When is Replimune (REPL) scheduled to present at the BMO 2024 Oncology Summit?
What activities will Replimune (REPL) engage in at the upcoming investor conferences?
On which stock exchange is Replimune (REPL) listed?
